- Home
- WLY vs CELC Comparison
WLY vs CELC Comparison
Compare WLY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- CELC
- Stock Information
- Founded
- WLY 1807
- CELC 2011
- Country
- WLY United States
- CELC United States
- Employees
- WLY N/A
- CELC N/A
- Industry
- WLY Books
- CELC Medical Specialities
- Sector
- WLY Consumer Discretionary
- CELC Health Care
- Exchange
- WLY Nasdaq
- CELC Nasdaq
- Market Cap
- WLY 2.2B
- CELC 2.3B
- IPO Year
- WLY N/A
- CELC 2017
- Fundamental
- Price
- WLY $36.86
- CELC $49.50
- Analyst Decision
- WLY
- CELC Strong Buy
- Analyst Count
- WLY 0
- CELC 6
- Target Price
- WLY N/A
- CELC $63.00
- AVG Volume (30 Days)
- WLY 333.0K
- CELC 1.0M
- Earning Date
- WLY 09-04-2025
- CELC 11-13-2025
- Dividend Yield
- WLY 3.86%
- CELC N/A
- EPS Growth
- WLY N/A
- CELC N/A
- EPS
- WLY 1.78
- CELC N/A
- Revenue
- WLY $1,670,600,000.00
- CELC N/A
- Revenue This Year
- WLY $1.45
- CELC N/A
- Revenue Next Year
- WLY $2.70
- CELC N/A
- P/E Ratio
- WLY $20.66
- CELC N/A
- Revenue Growth
- WLY N/A
- CELC N/A
- 52 Week Low
- WLY $36.10
- CELC $7.58
- 52 Week High
- WLY $53.96
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- WLY 37.86
- CELC 48.81
- Support Level
- WLY $37.93
- CELC $47.43
- Resistance Level
- WLY $40.90
- CELC $50.74
- Average True Range (ATR)
- WLY 0.81
- CELC 2.91
- MACD
- WLY -0.26
- CELC -0.96
- Stochastic Oscillator
- WLY 8.82
- CELC 40.20
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.